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Abstract
Background: Amphetamine and methamphetamine use disorders are associated with severe health and social
consequences. No pharmacological therapy has been approved for the treatment of these disorders.
Psychostimulants can act as maintenance-like therapies for managing substance use among these patients.
The aim of this study is to evaluate the literature examining the efficacy and safety of psychostimulant agents for
increasing abstinence and treatment retention among patients with amphetamine and methamphetamine use
disorders.
Methods: We searched MEDLINE, EMBASE, PsycInfo, Cochrane Central, and CINAHL from inception to August 2016.
Selection of studies, data extraction, and risk of bias assessment were conducted independently by two reviewers.
We conducted meta-analyses to provide a pooled summary estimate for included trials and report the review
according to PRISMA guidelines.
Results: We identified and selected 17 studies with 1387 participants. Outcome reporting across trials was inconsistent,
and the overall quality of evidence was very low due to high risk of bias and indirectness. A meta-analysis of five trials
(642 participants) found no effect of psychostimulants for end-of-study abstinence (odds ratio = 0.97, 95% confidence
interval 0.65 to 1.45). Additionally, the pooled estimate from 14 studies (1184 participants) showed no effect of
psychostimulants for treatment retention (odds ratio = 1.20, 95% confidence interval = 0.91 to 1.58). The incidence of
serious adverse events did not differ between intervention and placebo groups based on qualitative reports from trials.
Conclusions: Quantitative analyses showed no effect of psychostimulants for sustained abstinence or treatment
retention. We also identified the need for more rigorous studies in this research area with clinician and patient
important outcomes.
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Background
Amphetamine-type stimulants, including methampheta-
mine, amphetamine, and dextroamphetamine, are highly
addictive synthetic substances exhibiting increasing rates
of abuse among individuals with wide-ranging sociode-
mographic profiles [1]. Methamphetamine use, produc-
tion, and trafficking are significant problems in North
America, with 61% of global methamphetamine seizures
being reported within the continent in 2013 [2]. The use
and abuse of amphetamine-type stimulants is a major
public health concern given that initial exposure can
potentially progress into dependence as rapidly as within
a single week [1]. Amphetamine and methamphetamine
use disorders (AMD), encompassing both abuse and
dependence, are characterized by problematic patterns
of the use of amphetamine-type stimulants, leading to
development of tolerance and experiencing withdrawal
symptoms [1]. Regular use of amphetamine-type stimulant
substances can lead to adverse physical, psychological, and
social consequences. Frequent methamphetamine use is
associated with serious physical and psychological conse-
quences such as increased risk of infectious diseases,
cardiovascular pathology, cognitive impairment, severe
dental decay, depression, psychotic disorders, and mortal-
ity [3, 4]. Methamphetamine use is also associated with
social consequences such as aggression, violence, and
criminal activity [4, 5]. Currently, there are no approved
medications for the treatment of AMD [6, 7]. Psychosocial
therapies have shown positive outcomes, but results are
inconsistent for treatment retention and many trials show
no reduction in substance use at follow-up [8, 9]. A previ-
ous research has called for future work to determine
which medications are effective for relief of withdrawal
symptoms and to be used in combination with psycho-
social treatments [9]. Given the medical and social costs
of AMD, it is necessary to identify an effective harm
reduction therapy.
A number of randomized controlled trials (RCTs) have
investigated the effectiveness of psychostimulants as harm
reduction therapy for AMD. Psychostimulant agents are
generally dopamine (DA) agonists that increase synaptic
concentrations of DA with similar mechanisms of action
as abused amphetamines and methamphetamines [10].
Abused amphetamines and methamphetamines increase
synaptic concentrations of monoaminergic neurotransmit-
ters, including DA [10]. The expectation is for psychosti-
mulants to act as maintenance-type therapy for patients
with AMD to relieve withdrawal symptoms and drug
cravings, subsequently leading to reduced stimulant use.
Previous reviews have been published [6, 7, 10, 11], with
only the most recent review by Pérez–Mañá et al. [7]
conducting a meta-analysis. Pérez–Mañá and colleagues
[7] found no effect of psychostimulants for AMD. How-
ever, a number of trials have been conducted with
psychostimulants since the completion of this review. Our
systematic review will broaden eligibility criteria by
including adolescent and adult studies, and conducting
subgroup analyses by age group and frequency of sub-
stance use, which may have an effect on treatment out-
come [12, 13]. Pérez–Mañá et al. [7] reported that the
quality of evidence in this area was very low, indicating
that the new trials published since then may have a
substantial impact on the treatment outcome. Addition-
ally, due to the small sample size of individual trials, an
updated review is necessary to summarize the evidence.
The objective of the present review is to summarize the
efficacy and safety of psychostimulant medications for the
treatment of AMD in adolescents and adults. Specifically,
we aim to summarize the current literature examining the
efficacy of psychostimulant medications for (1) sustaining
abstinence from illicit amphetamines and methamphet-
amines and (2) retention in treatment by conducting risk of
bias and quality assessment of included trials, and comput-
ing quantitative pooled summary estimates. Secondary ob-
jectives of the review are to consider the potential modifiers
of psychostimulant treatment efficacy and summarize the
risk of serious adverse events (SAEs) related to psychosti-
mulant therapy, as reported by the included studies.
Methods
The following methods were established a priori in an
unpublished protocol that is available upon request
from the authors. The review was submitted to PROS-
PERO for registration but did not meet eligibility
criteria at the time of submission. The review is re-
ported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [14] and an additional file shows
the PRISMA checklist (see Additional file 1).
Data sources
The following databases were searched from inception
until August 2016: MEDLINE, EMBASE, PsycINFO,
Cochrane Central Library, and Cumulative Index to
Nursing and Allied Health Literature (CINAHL). A broad
search was employed in order to capture all relevant cita-
tions. An additional file outlines the search strategy, devel-
oped by the first author (M.B.) in collaboration with an
expert health sciences librarian (N.B.) (Additional file 2).
Furthermore, reference lists of past systematic reviews
and included trials were manually searched for relevant
studies. ClinicalTrials.gov was searched as a source for
unpublished and ongoing trials.
Inclusion and exclusion criteria
The search was limited to studies with human partici-
pants. However, all databases were searched without re-
strictions on language or date of publication. We
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included RCTs comparing the use of any psychostimu-
lant medication to an inactive control group (i.e., pla-
cebo) for the treatment of AMD. We excluded all study
designs that were not RCTs, including non-randomized
clinical trials and quasi-randomized studies. Participants
included adolescents and adults ≥14 years of age and
diagnosed with amphetamine or methamphetamine use
disorder (including those with abuse or dependence),
according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM) criteria. We included studies
that used clinician-administered or self-reported vali-
dated instruments for diagnosis of AMD. We also in-
cluded studies of participants diagnosed with DSM-5
criteria stimulant use disorder (including cocaine, am-
phetamine, and methamphetamine) and extracted rele-
vant data about patients with only AMD. Trials of
participants with cocaine use disorder alone were ex-
cluded. Studies examining the use of psychostimulants
or central nervous system stimulants for the treatment
of AMD were included in the review. Since “psychosti-
mulant” agents represent a pharmacological effect rather
than class of medications, a comprehensive list of these
agents is not available. Instead, psychostimulants are
dispersed over various pharmacological groups based on
their indication. We utilized an approach described by
Castells et al. [15] and Pérez–Mañá et al. [7] in previous
reviews of stimulant use disorders to obtain a compre-
hensive list of psychostimulants. We identified drugs
with psychostimulant modes of action from the Ana-
tomical Therapeutic Chemical Classification [16] and
the American Hospital Formulary Service Pharmaco-
logic–Therapeutic Classification System [17] and in-
cluded in the search strategy. The strategy included
psychoanaleptics with mild stimulant effects (bupropion,
modafinil) as well as classical stimulants (dextroamphet-
amine, methylphenidate, and dexmethylphenidate). Trials
managing withdrawal rather than dependence were ex-
cluded. Trials were excluded if they assessed non-substance
use outcomes, such as cognitive and neurological out-
comes, after in-lab administration of amphetamines or
methamphetamine.
Data collection and extraction
Two authors independently screened titles and abstracts
of all retrieved citations, excluding studies that failed to
meet eligibility criteria. Following title and abstract
screening, two authors independently reviewed full-texts
of relevant studies. Studies that satisfied all eligibility
criteria were included for data extraction. We used
Covidence systematic review software (Veritas Health
Innovation, Melbourne, Australia) for screening and full-
text review. We resolved disagreements during the
screening process by discussion to consensus. If they
remained unresolved, a senior author was consulted to
determine study eligibility. Two authors extracted data
from included trials using a pilot tested data extraction
form. An additional file includes the completed form with
details extracted from individual studies (see Additional
file 3), which was later exported into Review Manager
Version 5.3 (The Cochrane Collaboration) for statistical
analysis.
Risk of bias and quality assessment
Two raters independently assessed risk of bias of in-
cluded trials using the Cochrane Collaboration’s risk of
bias tool [18]. Scores of high, low, or unclear risk of bias
were assigned to trial factors including random sequence
generation, allocation concealment, blinding of partici-
pants, personnel and outcome adjudicators, incomplete
outcome assessment, selective reporting, and other
sources of bias. We assessed publication bias visually by
generating a funnel plot for primary outcomes. We used
the risk of bias assessment to support conclusions re-
garding the overall quality of evidence in the review. We
applied the Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) framework for
systematic reviews to the included trials to assign an
overall outcome-specific rating for risk of bias, inconsist-
ency, indirectness, imprecision, and publication bias
[19]. We used GRADE Pro GDT software (http://
gdt.guidelinedevelopment.org/app/) to create evidence
and summary of findings tables.
Data synthesis
We measured inter-rater agreement using the un-
weighted kappa statistic for full text review and risk of
bias assessment and conducted meta-analyses using
Review Manager Software Version 5.3 (The Cochrane
Collaboration, London, UK).
The primary outcomes of this review were (1) abstin-
ence from illicit amphetamines and methamphetamines
and (2) retention in treatment. Abstinence was measured
as the proportion of participants having substance-free
urine tests in intervention and control groups. The lon-
gest substance-free period of time assessed across mul-
tiple studies was used to determine sustained abstinence.
We measured treatment retention, or completion of
treatment, as the proportion of individuals remaining in
treatment at the end of the trial. The secondary outcome
was the incidence of SAEs for different psychostimulant
interventions in comparison with placebo. SAEs were
defined as any medical or psychiatric event causing
hospitalization or dropout from the study.
We summarized individual study results qualitatively
and conducted meta-analyses to obtain pooled summary
estimates (odds ratios), when interventions and outcomes
were comparable between trials. We pooled studies
broadly and conducted predetermined subgroup analyses
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to explore heterogeneity. We measured heterogeneity
using the inconsistency index (I2) for each meta-analysis,
with I2 >40% representing substantial heterogeneity. We
applied the random-effects model with inverse variance
methods for meta-analysis, as it accounts for within and
between-study variability and considerable variability is
expected between included trials [20]. We analyzed all
data according to the intention-to-treat principle with the
number of participants randomized being used as the
denominator. If multiple trials reported overlapping of
study participants, only the trial with the larger sample
was included in the meta-analysis so as to not to violate
the assumption of independence.
Subgroup analyses
We conducted the following a priori planned subgroup
analyses:
1. A subgroup analysis based on participant diagnosis
of amphetamine or methamphetamine use disorder
due to differences between individuals with the
different substance dependencies. It was
hypothesized that the effect would favor
participants with amphetamine use disorder due
to similarity of psychostimulant effect to that of
abused amphetamines.
2. A subgroup analysis comparison of different
psychostimulant interventions studied. It was
expected that dexamphetamine would have a
favorable effect compared to other psychostimulant
interventions due to similarity of structure to that
of abused amphetamine substances.
3. A subgroup analysis based on frequency of
amphetamine and methamphetamine use in the
past month (number of days). Less than daily use
of amphetamines or methamphetamines was
considered low frequency relative to studies
including any frequency of use. We expected that
studies examining lower baseline frequency of
substance use would demonstrate greater treatment
effect [12, 13].
4. A subgroup analysis based on age of participants, by
comparing adolescent or adult studies. Due to
challenges in treatment retention and overall
adherence to treatment among adolescent
populations, it was hypothesized that adult studies
would show greater treatment effect.
5. A subgroup analysis on duration of treatment
based on length ≤12 or >12 weeks of treatment.
It was expected that studies with >12 weeks of
treatment would show favorable effect, based on
previous substance use intervention studies
finding similar results for treatment programs
with longer duration.
We planned an additional subgroup analysis to com-
pare dosage of psychostimulant interventions but could
not conduct due to similar doses between studies exam-
ining the same medications.
Sensitivity analysis
We conducted sensitivity analyses by removing studies
with high risk of bias for each item on the Cochrane risk
of bias tool in order to evaluate the robustness of the sum-
mary estimates for each outcome. We also conducted a
sensitivity analysis by removing studies conducted within
specific high-risk populations (participants with attention-
deficit hyperactivity disorder, criminal offenders, and men
who have sex with men).
Results
Description of studies
Following screening of 1251 unique citations for eligibil-
ity, 17 studies were included for data extraction and
analysis in the review (Fig. 1). The unweighted kappa for
full-text review for two independent reviewers was 0.84.
We also calculated inter-rater agreement for the risk of
bias assessment, yielding a kappa statistic of 0.83, indi-
cating excellent levels of agreement between raters, as
per Cochrane Handbook cutoffs.
Seventeen studies were included in the systematic re-
view, all of which were parallel design RCTs published in
a peer-reviewed journal [12, 13, 21–35]. Table 1 displays
individual study characteristics of included trials and sum-
marizes substance use outcomes for all trials, including
those that are not included in the quantitative analysis.
Four different psychostimulant therapies were examined
in the included studies—modafinil [24, 34, 35], bupropion
[12, 13, 21, 22, 30, 33], methylphenidate [25–28, 31, 32],
and dexamphetamine/dextroamphetamine [23, 29].
Most studies enrolled participants with DSM–IV meth-
amphetamine dependence, while two studies recruited
participants with both amphetamine and methampheta-
mine dependence [28, 32]. Furthermore, two other studies
included participants with a diagnosis of amphetamine
dependence alone and comorbid attention-deficit hyper-
activity disorder (ADHD) [25, 26]. There was only one
trial conducted in adolescents [33], while the remaining
trials were within adult samples, 18–65 years of age. The
adolescent study was conducted among participants
with ≤18 days of methamphetamine use in the month
prior to baseline interview [33]. Two other studies were
conducted among low-frequency adult methampheta-
mine users (≤29 days in the month prior to baseline
interview) [12, 13]. Men comprised >60% of the study
sample in many studies, and two studies included only
men [21, 26]. Among those studies, Das et al. [21]
specifically included men who have sex with men, a
population at increased risk of methamphetamine use
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and abuse. A number of studies excluded individuals
diagnosed with comorbid substance use disorders [13,
24–26, 28–30, 33, 35].
The majority of trials administered the psychostimu-
lant intervention for 8–12 weeks, while few studies had
longer treatment duration (20–24 weeks) [25, 28, 32].
Doses of medications were relatively consistent within
psychostimulant type: however, the dose varied between
different types of psychostimulants. All studies investi-
gating modafinil administered doses of 200 mg, with the
exception of study by Anderson et al. [35] having a
second treatment group receiving 400 mg of modafinil.
For the Anderson [35] trial, the number of events from
the 200 and 400 mg treatment groups was combined in
the meta-analysis and compared to the placebo group. Bu-
propion was consistently given in doses of 150 mg twice
daily, and the maximum dose of methylphenidate ranged
from 54 to 180 mg between studies. There were two trials
of dextroamphetamine/dexamphetamine—both stabilizing
participants at different doses. All trials were placebo-
controlled, although most trials did not report the inactive
substance in the placebo capsule. Two trials used lactose
[23, 27] and one used gelatin [32] as the inactive substance
in the placebo group.
Risk of bias assessment
Figures 2 and 3 display a summary of the risk of bias
assessment, conducted in duplicate by the review au-
thors using the Cochrane risk of bias tool. A number of
studies had unclear or high risk for at least one meth-
odological criterion. Random sequence generation was
adequately reported in less than half of the trials, and
over 75% of the trials did not report allocation conceal-
ment adequately. While 16 of the 17 trials implemented
blinding of participants and study personnel, all trials
had unclear or high risk of bias for blinding of outcome
assessment.
Fig. 1 PRISMA flow diagram for the study selection process
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with any frequency of
use
16 weeks Modafinil/200 or 400 mg once
daily on awakening
210 (59.1% male) Modafinil 200 mg
37.6 (8.9)
Modafinil 400 mg 40
(8.4)
Placebo 39.4 (8.6)
No significant difference in MA non-use weeks (p = 0.53, GEE),
MA non-use days (p = 0.63, overall Kruskal–Wallis) or terminal







frequency users (≤29 of
past 30 days)
12 weeks Bupropion/150 mg twice daily 204 (65% male) Total sample 39.3
(NR)
Treatment success, defined as ≥2 negative urines in weeks 11
and 12, was achieved by 14% (14/100) of the bupropion group





men having sex with
men
12 weeks Bupropion/150 mg 1 pill every
morning for 1 week, then 2 150
mg pills every morning thereafter
30 (100% male) Bupropion 38.1 (2)
Placebo 33.3 (3)
Reductions in meth-metabolite-positive urines were similar in







with any frequency of
use
18 weeks Bupropion/150 mg once daily for
3 days, then increased to 300 mg
daily (1 tablet twice a day) for
11 weeks
151 (67% male) Bupropion 36.2 (9.2)
Placebo 35.7 (8.4)
No significant improvement for percentage of participants with
MA-free study weeks in the bupropion group (week 1 = 25%;
week 12 = 54%) compared to placebo (week 1 = 29%; week 12
= 44%)






with any frequency of
use
8 weeks Dextroamphetamine/60 mg
daily—single dose on the first
day and as 2 equally divided
doses on subsequent days
60 (56.7% male) Dextroamphetamine
37 (7.2)
Placebo 37.5 (7.2)
Out of 16 urine tests over the 8-week trial period, the dextro-
amphetamine group had 2.9 ± 4.3 MA-negative results and the
placebo group had 3.2 ± 5.0 MA-negative results (Mann–Whit-






with any frequency of
use
14 weeks Modafinil/200 mg per day
(taken in the morning)
for the first 3 days of the study,
followed by an increase to 400 mg
per day (in the morning)
71 (70.4% male) Modafinil 39.1 (11.1)
Placebo 37.8 (10.1)
No significant association between treatment group
assignment and the probability of providing MA-free urine
drug screens across the treatment period (OR = 0.78, 95% CI







low frequency users (≤18
of past 30 days)
8 weeks Bupropion/150 mg twice daily 19 (47.4% male) Bupropion 17.5 (1.6)
Placebo 17.7 (1.1)
Mean number of twice weekly MA-negative urine screens in






frequency users (≤29 of
past 30 days)
16 weeks Bupropion/150 mg once daily f
or 3 days, then 150 mg twice daily
84 (80.9% male) Bupropion 38.6 (10.1)
Placebo 38.1 (10.3)
No significant difference in the proportion of participants with
MA abstinence during weeks 11 and 12, for bupropion = 12/41









13 weeks Methylphenidate/18 mg starting
dose titrated over period of 10
days to the maximum dose of
72 mg
24 (75% male) Methylphenidate
34.6 (10.1)
Placebo 39.7 (9.8)
No significant difference in proportion of positive urine screens
during the study between methylphenidate (mean = 10.6, SD









24 weeks Methylphenidate/18 mg starting
dose titrated over a period of 19
days (with 36 mg increments every
54 (100% male) Methylphenidate 41
(7.5)
Placebo 42 (11.7)
Significant difference in proportion of drug-negative urines in
methylphenidate group (MD = 23%, n = 27) compared to pla-












Table 1 Individual study characteristics (17 included studies) (Continued)







with any frequency of
use
14 weeks Methylphenidate/18 mg daily for
week 1, 36 mg for week 2 and
54 mg for weeks 3–10
110 (81.8% male) Methylphenidate
38.7 (9.8)
Placebo 39.5 (10.4)
Methylphenidate group was less likely to be MA positive






with any frequency of
use
12 weeks Dexamphetamine/20 mg/day
starting dose increased by
10 mg daily as required until
stabilized or to a maximum
of 110 mg/day (stabilized
over 14 days)
49 (61.2% male) Dexamphetamine
31.9 (4.5)
Placebo 31.9 (5.6)
Significant decrease of MA concentration in hair for both
groups (p < 0.0001) but no significant difference between









any frequency of use
22 weeks Methylphenidate/18 mg/day
for the first week, 36 mg daily
for the second week and 54
mg daily thereafter until the
end of week 22
78 (62.8% male) Methylphenidate
38.9 (9.2)
Placebo 34 (8.5)
No significant difference in mean percentage of positive urine
tests over the course of the study between methylphenidate
(mean = 89%, SD = 19) and placebo (mean = 90%, SD = 14)






with any frequency of
use
10 weeks Methylphenidate/18 mg/day
during the first week and
36 mg/day during the second
week and then received 54
mg/day for the remaining 8 weeks
56 (73.2% male) Methylphenidate
35.6 (6.9)
Placebo 34.7 (9.1)
Methylphenidate group had significantly less MA-positive urine






users (2–3 days of use
per week or more)
22 weeks Modafinil/200 mg/day 80 (62.5% male) Modafinil 35.8 (6.9)
Placebo 36.1 (9.1)
No significant difference in proportion of stimulant-positive







with any frequency of
use
12 weeks Bupropion/150 mg per day for
days 1–3, followed by an increase
to 300 mg per day (one 150 mg
capsule taken twice daily) until
week 12
73 (64.4% male) Bupropion 34.6 (10.6)
Placebo 34.6 (10.0)
No significant difference between treatment groups in the
mean MA-free urine screens or the probability of achieving a
MA-free week in a GEE model (chi-square = 0.004, degrees of








20 weeks Methylphenidate/18 mg/day for
the first week, 36 mg/day for the
second week, and 54 mg/day
thereafter
34 (70.6% male) Methylphenidate
35.1 (7.9)
Placebo 40 (10.1)
Significantly fewer positive urine samples in methylphenidate
group compared to placebo group (OR = 0.42, 95% CI = 0.24–
0.72; z = −3.14, p = 0.002)
All studies used an inactive placebo pill of the same dosage as the intervention for the control group. The substance use outcomes are summarized as they are reported in the individual studies












Attrition was a major drawback in most trials, with
>50% of participants dropping out before study com-
pletion. However, the majority of trials conducted an
intention-to-treat analysis and had similar proportions
of dropout in intervention and placebo groups. High
risk of bias for incomplete outcome data was still an
issue for 50% of the trials when reasons for dropouts
were not stated, and it could not be determined
whether reasons for dropout were similar for inter-
vention and control groups. Risk of bias due to se-
lective outcome reporting was primarily low, although
study outcomes were reported inconsistently between
trials.
All studies required written informed consent from
participants and reported approval from an ethics review
board. The majority of trials were not industry funded,
but some study authors reported a conflict of interest.
Other bias resulted from significant conflicts of interest
(as judged by the rater), imbalanced randomization
judged to have potential impact on the outcome, and
underpowered based on presented sample size/power
calculation. There were also a few studies with 17 or less
participants in each treatment arm, which were likely
biased towards type II errors due to small sample sizes
[21, 25, 32, 33].
Meta-analyses: efficacy of psychostimulants for
abstinence from illicit amphetamine and
methamphetamine
Five out of 17 included studies were included in the pri-
mary meta-analysis for abstinence from illicit amphet-
amines or methamphetamines [12, 13, 24, 30, 35]. All of
the five studies included in the meta-analysis included par-
ticipants with methamphetamine dependence (regular or
low frequency of use) and measured “terminal abstinence,”
defined as methamphetamine-free urine screens during
the final 2 weeks of the trial. The remaining studies were
excluded from the meta-analysis because outcomes were
not reported consistently, and the studies lacked sufficient
information to determine the number of participants with
sustained abstinence in intervention and control groups.
Figure 4a shows the pooled summary estimate, based
on five studies and a total sample size of 642 individuals.
Of these participants, 353 received psychostimulant
therapy and 289 received placebo. The pooled odds ratio
for sustained abstinence was 0.97 (95% confidence inter-
val 0.65 to 1.45, p value = 0.87), representing no signifi-
cant effect of psychostimulants on abstinence from
methamphetamines. This summary estimate was associ-
ated with low statistical heterogeneity, as indicated by an
I2 of 2% (chi-square = 4.08, degrees of freedom = 4, p
Fig. 3 Risk of bias assessment based on author judgment for individual studies
Fig. 2 Summary graph of author judgments for each risk of bias criteria
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value = 0.40). Sources of heterogeneity were explored by
conducting a priori specified subgroup analyses.
Subgroup analyses
Due to inclusion of five trials in the meta-analysis, we
were unable to conduct subgroup analyses based on age
(adolescent or adult), substance use disorder (amphet-
amine or methamphetamine use disorder), or treatment
duration. The first subgroup analysis was conducted
based on psychostimulant intervention. The modafinil
group was associated with no heterogeneity (I2 = 0%, p
value = 0.78), while the bupropion group showed
Fig. 4 a Forest plot for efficacy of psychostimulants on abstinence from illicit amphetamines or methamphetamines (measured by urinalysis). b
Subgroup analysis by psychostimulant medication on abstinence from illicit amphetamines or methamphetamines. c Subgroup analysis by
frequency of substance use on abstinence from illicit amphetamines or methamphetamines
Bhatt et al. Systematic Reviews  (2016) 5:189 Page 9 of 17
substantial heterogeneity (I2 = 47%, p value = 0.15). How-
ever, both modafinil (OR = 0.86, 95% CI 0.46 to 1.61, p
value = 0.65) and bupropion (OR = 1.12, 95% CI 0.54 to
2.33, p value = 0.76) showed no effect for sustained ab-
stinence (Fig. 4b). The test for subgroup differences was
not significant (I2 = 0%, chi-square = 0.29, degrees of
freedom = 1, p value = 0.59).
The second subgroup analysis was conducted for fre-
quency of substance use and showed high heterogeneity
among studies with low frequency (i.e., non-daily) sub-
stance users (I2 = 74%, p value = 0.05). Figure 4c shows the
forest plot. Studies with unspecified frequency of use were
associated with no heterogeneity (I2 = 0%, p value = 0.91).
However, both low frequency (OR = 1.24, 95% CI 0.34 to
4.48, p value = 0.74) and unspecified frequency (OR = 0.92,
95% CI 0.54 to 1.54, p value = 0.74) substance use groups
showed no effect for abstinence. The test for subgroup dif-
ferences was again associated with no heterogeneity but
remained non-significant (I2 = 0%, chi-square = 0.18, de-
grees of freedom = 1, p value = 0.67).
Meta-analyses: efficacy of psychostimulants for retention
in treatment
Fourteen studies were included in the meta-analysis for
the outcome of retention in treatment, defined as the
proportion of participants that completed the study
(Fig. 5a). Two studies were excluded because informa-






Fig. 5 a Forest plot for efficacy of psychostimulants on retention in treatment. b Subgroup analysis by substance use disorder on retention in
treatment. c Subgroup analysis by psychostimulant medication on retention in treatment. d Subgroup analysis by frequency of substance use on
retention in treatment. e Subgroup analysis by treatment duration on retention in treatment
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number of paticipants retained in treatment [32, 33],
and a study by Elkashef et al. [22] was excluded due to
an overlapping sample with Anderson et al. [12]. The
pooled summary estimate was based on a collective 1184
participants, of whom 626 received psychostimulant inter-
ventions and 558 received placebo. The pooled OR (1.20)
was non-significant (95% CI 0.91 to 1.58) and was associ-
ated with low heterogeneity (I2 = 15%, chi-square = 15.34,
degrees of freedom = 13, p value = 0.29). We explored
sources of heterogeneity by prespecified subgroup
analyses, but did not conduct a subgroup analysis of age
because the adolescent study was excluded from the
meta-analysis due to insufficient outcome data [33].
Subgroup analyses
The first subgroup analysis was based upon study inclu-
sion of participants with amphetamine use disorder and
methamphetamine use disorder (Fig. 5b). The test for sub-
group differences was not statistically significant (I2 = 0%,
chi-square = 0.28, degrees of freedom = 1, p value = 0.59).
The amphetamine use disorder subgroup was associated
with substantial heterogeneity (I2 = 57%) based on the cut-
off of high heterogeneity at >40%, and the pooled OR of
1.54 was not statistically significant (95% CI 0.48 to 4.99, p
value = 0.47). The methamphetamine use disorder sub-
group was associated with no heterogeneity (I2 = 0%), and
a non-significant overall OR of 1.11 (95% CI 0.86 to 1.44,
p value = 0.42). The test for subgroup differences was
associated with no heterogeneity but was not significant
(p value = 0.59).
We conducted a second subgroup analysis by specific
type of psychostimulant medication, varying between
two to six studies within the subgroups (Fig. 5c). A test
for differences in effect between the aforementioned
subgroups was not significant (chi-square = 2.31, degrees
of freedom = 3, p value = 0.51), but associated with no
heterogeneity (I2 = 0%). No subgroups of psychostimulants
showed a significant OR for treatment retention, and only
the methylphenidate subgroup was associated with sub-
stantial heterogeneity (I2 = 43%, p value = 0.13). There was
a trend in both studies of dexamphetamine for favorable
effects of psychostimulants; however, there was no signifi-
cant pooled effect (OR = 2.50, 95% CI 0.80 to 7.87, p value
= 0.12) and the 95% confidence interval was wide.
We conducted the third subgroup analysis (Fig. 5d)
based upon frequency of substance use disorder. As pre-
viously defined, low frequency of substance use was
characterized as substance use ≤29 days in the past
month (i.e., non-daily substance use) and was compared
to studies including participants with unspecified fre-
quency of substance use. None of the subgroups showed
a statistically significant pooled estimate for treatment
retention; however, the low frequency subgroup only in-
cluded two studies. The test for subgroup differences
showed no heterogeneity and was not significant (chi-
square = 0.05, degrees of freedom = 1, p value = 0.83).
The final subgroup analysis for this outcome was based
on treatment duration, categorized as ≤12 weeks or
>12 weeks (Fig. 5e). The test for subgroup differences was
borderline significant and associated with substantial het-
erogeneity (I2 = 74.5%, chi-square = 3.93, degrees of free-
dom = 1, p value = 0.05). The subgroup of studies with
≤12 weeks of treatment did not find a significant pooled
OR. The pooled estimate of two studies >12 weeks was
significant and associated with no heterogeneity. Results
showed twice the increased odds of retention in treatment
>12 weeks for the psychostimulant group with an OR =
2.45 (95% CI 1.14 to 5.25, p value = 0.02).
Psychostimulant safety: adverse events
Three of the 17 studies utilized a standardized instru-
ment for investigating differences in adverse events be-
tween psychostimulant and placebo groups [23, 28, 34],
while the remaining studies reported observed adverse
events. Miles et al. [28] measured adverse events using
the Udvalg Kliniske Undersogelser and found no differ-
ences between methylphenidate and placebo arms.
Shearer et al. [34] reported no statistically significant
univariate differences in mild, moderate, or serious ad-
verse events between modafinil and placebo groups.
Similarly, Galloway et al. [23] found no differences in re-
ported adverse events between dextroamphetamine and
placebo groups. Across all studies, mild adverse events
differed by psychostimulant medication but these mild
symptoms were not associated with dropout or discon-
tinuation of medication in most studies.
While a number of studies reported SAEs including
hospitalization due to suicidal ideation, seizures, pneu-
monia, and others, no study stated that the SAEs or
dropouts were associated with active study medication.
However, there was high inconsistency in reporting of
adverse events, and it was often unclear whether SAEs
resulted in complete discontinuation from the study.
From the available information, we found there were 8
dropouts from modafinil groups [24, 34, 35], 11 from
bupropion [12, 13, 22, 30], and 7 from methylphenidate
[27] (26 total) and a total of 11 from placebo groups [13,
22, 24, 26–28, 30].
Sensitivity analyses
We conducted sensitivity analyses by removing studies
within sub-populations one at a time. Das (2010) in-
cluded a sample of men who have sex with men, Konste-
nius et al. [25] comprising of adults with comorbid
ADHD, and Konstenius et al. [26] of men who are crim-
inal offenders with ADHD were removed, but there were
no differences in the results of the meta-analyses for the
primary outcomes. Additionally, the pooled estimate did
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not change significantly for either primary outcome
when we removed studies with high risk of bias for “se-
lective outcome reporting” and “incomplete outcome
data” one at a time.
Publication bias
Figure 6a, b show funnel plots assessing publication bias
for treatment retention. Figure 6a generates using the
five studies from the meta-analysis assessing abstinence
from amphetamine and methamphetamine use. The left
side of the plot favors placebo, and the right side of the
plot favors psychostimulants with regard to increased
odds of abstinence from illicit stimulants. There is no
evidence of asymmetry in the funnel plot based on five
of the 17 included studies. However, it is expected that
the plot will remain symmetrical after addition of the
remaining studies since a number of studies with
negative results have been published. Figure 6b assesses
publication bias for treatment retention based on 14 in-
cluded studies. There is likely no publication bias since
Fig. 6 a Funnel plot for abstinence from illicit substances. b Funnel plot for retention in treatment
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the plot shows point estimates in the left lower quad-
rant, indicating that that negative findings of psychosti-
mulant treatment effect have been published regardless
of the study size.
Discussion
This systematic review included 17 trials investigating
the efficacy and safety of psychostimulants in patients
diagnosed with AMD. Five out of 17 studies were in-
cluded in the meta-analysis for the primary outcome of
sustained abstinence. Studies included in the meta-
analysis for abstinence all investigated psychostimulants
for methamphetamine dependence, and no effect was
found for this outcome. Subgroup analyses of abstinence
also found no effect. For the outcome of treatment re-
tention, 14 studies were included in the meta-analysis
and the odds ratio was pooled. Overall, we found no sig-
nificant effect of psychostimulants on treatment reten-
tion. However, the subgroup analyses for treatment
retention demonstrated favorable effects for treatments
with longer duration (>12 weeks). The literature has
shown that patients enrolled in longer duration general
substance use treatment programs tend to have more
successful treatment outcomes [36]. These results are in-
teresting because they indicate that participants in lon-
ger duration studies are at increased odds of retention
until the end of treatment: however, this finding is based
on a subgroup of two studies and cannot be generalized
for all samples [26, 28]. It is possible that longer dur-
ation treatment may also show increased effectiveness
for substance use outcomes such as abstinence from am-
phetamines and methamphetamine, which is important
to examine with further research. However, this finding
of higher retention may also be due to factors such as
standard of care, including improved therapeutic alliance
or counseling community, in longer duration studies. As
well, continued participation may have occurred due to
expectation of early parole or fear of extended incarcer-
ation in the sample of criminal offenders recruited from
prisons [26]. In the remaining subgroup analyses, we
found no significant effects, although the direction of ef-
fects was consistent with our hypotheses. Other reviews
have reported modafinil to be effective in reducing am-
phetamine and methamphetamine use [6, 9]; however,
these reviews did not quantitatively summarize the re-
sults. The present review found no effect of modafinil or
bupropion on sustained abstinence from substances in
the meta-analysis.
There was a high level of inconsistency in reporting
adverse events and safety outcomes among included
studies; therefore, the overall observed number of SAEs
was determined for each psychostimulant intervention
and placebo groups. There were no clear differences in
reported adverse events based on raw numbers between
intervention and placebo groups. However, adverse
events may have been impacted by imperfect collection
and reporting methods, since only three of 17 studies
used standardized instruments to collect adverse event
data [23, 28, 34]. Development of adverse event report-
ing standards for RCT’s in this area and transparent
reporting of the methods used to ascertain whether
SAEs were associated with study medication is neces-
sary. This is especially important due to the increasing
number of trials conducted in recent years, which have
shown no effect for reduction of substance use [12, 13,
28, 33]. While it remains challenging to conduct clinical
trials in the field of substance use disorders, improving
the quality of future trials is important to detect a true
treatment effect that is not significantly impacted by
methodological limitations.
Previous reviews for pharmacological interventions
have been conducted for general stimulant dependence
[6, 9–11, 37]; however, most reviews provide narrative
summaries of results whereas only the most recent re-
view is specific to AMD patients and conducts meta-
analyses [7]. Since the publication of the recent review
by Pérez–Mañá et al. [7], a reasonable number of new
trials examining psychostimulants have been conducted
[12, 13, 26–28, 31]. Though new trials in this area are
being conducted, the methodology and reporting of out-
comes remains largely unchanged, making it challenging
to utilize trial results for quantitative analysis in system-
atic reviews. Substance use outcomes across the RCTs
include the proportion of negative urine screens within a
group, mean methamphetamine non-use days or weeks,
longest period of time abstinent in days or weeks, mean
number of negative urine screens, and number of partic-
ipants with terminal or end-of-trial abstinence. Lack of
uniformity in outcome reporting among trials investigat-
ing pharmacological therapies for AMD has resulted in
several recent trials reporting group level outcomes such
as overall proportion of negative urine screens in each
trial arm [21, 26, 28, 31, 32, 34]. Group level outcomes
make it difficult to ascertain the effect of psychostimu-
lant treatment on individual patients. In their systematic
review, Pérez–Mañá et al. pooled the mean difference in
number of negative urine screens per group as their pri-
mary outcome. Although this is an important outcome,
it is statistically inappropriate to pool as a continuous
outcome since the number of urine screens is a discrete
value with some trials conducting as few as 10 urine
tests [31]. For this reason, it is important for clinicians
to identify a minimum clinically significant number of
negative urine screens needed to achieve “success” in
harm reduction treatment. This can allow future clinical
trials to quantify the number of individuals achieving
success in intervention and control groups as a dichot-
omous outcome and conduct a responder analysis [38].
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However, this approach is also limited since there is cur-
rently no established threshold for negative urine screens
needed to be “successful” in substance abuse treatment.
More than half of the trials were judged to have high
risk of bias for at least one measure on the Cochrane
risk of bias tool. The majority of studies did not mention
allocation concealment, and incomplete outcome data
(attrition) was a major source of bias. However, studies
did conduct intention-to-treat analyses to compensate
for the high attrition rate. Moreover, included trials had
small samples (47% of trials had ≤30 participants per
trial arm) and may have been underpowered to detect
an effect at the individual study level. The GRADE evi-
dence profile (Table 2) and summary of findings (Table 3)
display the overall quality of evidence as assessed using
the GRADE framework and can be used to appraise the
certainty of findings from this review. For the outcome of
abstinence, risk of bias was very serious due to lack of allo-
cation concealment and incomplete outcome data; how-
ever, treatment retention was only affected by lack of
allocation concealment. There was a relatively low hetero-
geneity between studies for both primary outcomes;
Table 2 GRADE evidence profile
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CI confidence interval, OR odds ratio
aThe majority of studies had high attrition bias (>50% dropout rate) and small sample sizes
b80% of studies did not mention allocation concealment, which may be a source of bias
cHeterogeneity was not explained by subgroup analyses, as indicated by non-significant tests for subgroup differences
dStudies investigating the efficacy of different psychostimulant drugs at varying doses were pooled
e95% confidence intervals are wide and there is a varying range of effect, with little overlap of confidence intervals from some studies
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GRADE working group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility
that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
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intervention (and its 95% CI)
CI Confidence interval, OR Odds ratio
aThe majority of studies had high attrition bias (>50% dropout rate) and small sample sizes
b80% of studies did not mention allocation concealment, which may be a source of bias
cHeterogeneity was not explained by subgroup analyses, as indicated by non-significant tests for subgroup differences
dStudies investigating the efficacy of different psychostimulant drugs at varying doses were pooled
e95% confidence intervals are wide and there is a varying range of effect, with little overlap of confidence intervals from some studies
fPopulations varied across studies with certain studies including injection drug users, incarcerated individuals or participants with ADHD
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however, existing heterogeneity was not explained by sub-
group analyses given that the tests for subgroup differences
were not significant. Indirectness of the population and in-
terventions affects the quality of the evidence. Many studies
had strict eligibility criteria that excluded patients with co-
morbid substance use disorders [13, 24–26, 28–30, 33, 35],
whereas patients in clinical practice frequently present with
multiple substance use disorders [39]. Furthermore, some
trials were conducted in specific populations such as indi-
viduals with ADHD, incarcerated individuals, or men who
have sex with men [21, 25, 26]. Psychostimulant interven-
tions may have differential treatment effects within such
specific populations diagnosed with AMD. The ORs for ab-
stinence and treatment retention varied across studies, with
little to no overlap of 95% confidence intervals of individual
study point estimates. There was no evidence of publication
bias for either outcomes based on visual assessment of fun-
nel plots. Overall, the quality of evidence in the review can
be considered very low based on the GRADE assessment.
Strengths and limitations
This systematic review was conducted with an a priori
design to assess the efficacy and safety of psychostimu-
lants for AMD. We conducted a comprehensive search
of psychostimulant agents and two reviewers independ-
ently conducted title and abstract screening, full text
review, risk of bias assessment, and data extraction. This
is the largest review conducted to date investigating psy-
chostimulant agents for AMD including 17 RCTs; how-
ever, we were limited by the quality of evidence in
individual trials. Reporting of outcomes across studies
was very inconsistent and did not allow us to pool all of
the available data. Furthermore, we only included pub-
lished and available data from included trials rather than
obtaining additional data for analyses. Published data
were used in order to comment on the quality of out-
come reporting in RCTs in this area. Clinician and pa-
tient important outcomes were chosen as primary and
secondary outcomes for this review rather than group
level outcomes reported by individual studies. Neverthe-
less, the small number of trials in the meta-analysis for
abstinence limits the generalizability of the findings. As
well, we created broad eligibility criteria to include ado-
lescent studies, yet only one trial has been conducted
that has found inversely significant results. For this rea-
son, results of this review cannot be generalized to ado-
lescent populations.
Conclusions
The present systematic review found no effect of psy-
chostimulant agents on sustained abstinence or reten-
tion in treatment among patients diagnosed with AMD.
The majority of trials included participants with a diag-
nosis of methamphetamine dependence and were
12 weeks in treatment duration. Review findings suggest
that longer duration treatment may have a favorable ef-
fect for retention in treatment. Future trials in this area
should consider varying lengths of treatment (>12 weeks)
to determine whether duration is associated with reduc-
tion in substance use and abstinence. The current qual-
ity of evidence is very low, and future research may have
an impact on treatment outcomes. Future research
should utilize standardized methods of reporting out-
comes, including adverse events, such that a comprehen-
sive summary of evidence can be produced to eventually
inform clinical practice guidelines. While there are major
challenges in conducting clinical trials among substance
use disorder populations, identifying important out-
comes in the area and consistent reporting of outcomes
is integral in combining trial results to be used in mak-
ing clinical recommendations. If adequate outcome
reporting and high caliber methodology in future trials
continues to show no efficacy of psychostimulant inter-
ventions across multiple trials, this may indicate the
need to consider new treatment approaches for AMD.
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